

## Schriftenverzeichnis

1. R.Appel und M.Montenarh. Notiz über ein neues Verfahren zur Darstellung von Organylsulfonylisocyanaten. *Chem. Ber.* 107, 706-709 (1974).
2. R.Appel, H.Uhlenhaut und M.Montenarh. Cyclisierungsreaktion zwischen Chlorsulfonylisocyanat und Bis(trimethylsilylimido)schwefeloxid. *Z. Naturforsch.* 29B, 799 (1974).
3. R.Appel und M.Montenarh. Reaktionen von N,N-Dialkyl- und N,N-Diarylsulfamiden mit Chlorsulfonylisocyanat. *Chem. Ber.* 108, 618-622 (1975).
4. R.Appel, M.Montenarh und I.Ruppert. Über die Cycloaddition von Sulfonylisocyanaten mit Tetraschwefeltetranitrid. *Chem. Ber.* 108, 582-588 (1975).
5. R.Appel und M.Montenarh. Silylierungsreaktionen an Amidoschwefelsäurederivaten. *Chem. Ber.* 108, 1442-1446 (1975).
6. R.Appel und M.Montenarh. Darstellung und Reaktionen silylierter Amidoschwefelsäurederivate mit Schwefel(IV)-halogeniden. *Chem. Ber.* 108, 2340-2348 (1975).
7. R.Appel und M.Montenarh. Reaktionen mit monosilylierten Schwefel- und Carbodiimiden. *Z. Naturforsch.* 30B, 847-849 (1975).
8. R.Appel und M.Montenarh. Reaktionen von Sulfonylisocyanaten mit Schwefeldiimiden. *Chem. Ber.* 109, 2437-2441 (1976).
9. R.Appel, I.Ruppert und M.Montenarh. Schwefeltrioxid-Einschiebung an silylierten Iminophosphoranen. *Chem. Ber.* 109, 71-75 (1976).
10. M.Montenarh und R.Appel. Kondensationsreaktionen von silylierten Sulfamiden mit Trithiadiazylchlorid. *Z. Naturforsch.* 31B, 902-904 (1976).
11. R.Appel und M.Montenarh. Darstellung sulfamoylsubstituierter Silazane. *Z. Naturforsch.* 31B, 993-994 (1976).
12. R.Appel und M.Montenarh. Additionsreaktionen von N,N-Dialkylsulfamiden, tertiären Aminen und Phosphinen mit Fluorsulfonylisocyanat. *Chem. Ber.* 110, 2368-2373 (1977).
13. R.Appel und M.Montenarh. Spiro-bis-(1,1-dioxo-2,4-bis(trimethylsilyl)-1,6,2,4,2-thiadiazasiletidin), ein neues Spirosilazan. *Z. Naturforsch.* 32B, 10 (1977).
14. R.Appel und M.Montenarh. Reaktionen von silylierten Amidoschwefelsäuren und Sulfonamiden mit Schwefelchloriden. *Chem. Ber.* 111, 759-763 (1978).
15. M.Montenarh und R.Henning. Simian Virus 40 T-antigen phosphorylation is variable. [FEBS Letters 114, 107-110 \(1980\)](#).
16. M.Montenarh und R.Henning. Influence of the phosphorylation of simian virus 40 T-antigen on its binding to DNA and phosphocellulose. *Biochem. Soc. Trans.* 9, 234 (1981).
17. M.Montenarh und R.Henning. The binding of simian virus 40 large T antigen to the polyphosphate backbone of nucleic acids. [Biochim. Biophys. acta 697, 322-329 \(1982\)](#).
18. M.Montenarh, W.Deppert und R.Henning. Mapping of a DNA-binding domain of simian virus 40 T-antigen using non-defective adenovirus 2-simian virus 40 hybrid viruses. [FEBS Letters 142, 129-132 \(1982\)](#).
19. M.Montenarh und R.Henning. Disaggregation and reconstitution of oligomeric complexes of simian virus 40 large T-antigen. [J. Gen. Virol. 64, 241-246 \(1983\)](#).
20. M.Montenarh und R.Henning. Self-assembly of simian virus 40 large T antigen oligomers by divalent cations. [J. Virol. 45, 531-538 \(1983\)](#).
21. M.Montenarh, M.Kohler und R.Henning. Oligomerization of simian virus 40 large T antigen is not necessarily repressed by temperature-sensitive A gene lesions. [J. Virol. 49, 658-664 \(1984\)](#).
22. H.W.Stürzbecher, M.Mörke, M.Montenarh und R.Henning. Relationship of the phosphorylation to the oligomerization of SV40 T antigen and its association with p53. [FEBS Letters 180, 285-290 \(1985\)](#).
23. C.Schürmann, M.Montenarh, M.Kohler und R.Henning. Oligomerization of simian virus 40 (SV40) tumor antigen may be involved in viral DNA-replication. [Virology 146, 1-11 \(1985\)](#).
24. M.Montenarh, M.Kohler, G.Aggeler und R.Henning. Structural prerequisites of simian virus 40 large T antigen for the maintenance of cell transformation. [EMBO J. 4, 2941-2947 \(1985\)](#).
25. M.Montenarh, C.Vesco, G.Kemmerling, D.Müller und R.Henning. Regions of SV40 large T antigen necessary for oligomerization and complex formation with the cellular oncoprotein p53. [FEBS Letters 204, 51-55 \(1986\)](#).
26. M.Montenarh, M.Kohler und R.Henning. Complex formation of simian virus 40 large T antigen with cellular protein p53. [J. Virol. 60, 761-764 \(1986\)](#).
27. M.Montenarh, C.Vesco, und K.-H.Scheidtmann. Dimers and complexes with p53 constitute the oligomeric forms of a transforming non-karyophilic T antigen of simian virus 40. [J. Virol. 61, 940-944 \(1987\)](#).
28. M.Montenarh und D.Müller. Properties of SV40 T antigen from two point mutants affecting the phosphorylation of T antigen. *J. Cancer Res. Clin. Oncol.* 113, 34 (1987).

29. H.-W. Stürzbecher, M. Montenarh und R. Henning. Enhanced protein phosphorylation in SV40-transformed and infected cells. [Virology 160, 445-455 \(1987\)](#).
30. D. Müller, I. Ugi, K. Ballas, P. Reiser, R. Henning und M. Montenarh. The AT-rich sequence of the SV40 control region influences the binding of SV40 T antigen to binding sites II and III. [Virology 161, 81-90 \(1987\)](#).
31. M. Montenarh und D. Müller. The phosphorylation at Thr 124 of simian virus 40 large T antigen is crucial for its oligomerization. [FEBS Lett. 221, 199-204 \(1987\)](#).
32. G. Stetter, D. Müller und M. Montenarh. SV40 T antigen binding to site II functionally separated from binding to site I. [Virology 164, 309-317 \(1988\)](#).
33. M. Mörike, A. Quaiser, D. Müller und M. Montenarh. Stimulation of quiescent NIH3T3 cells by serum or purified simian virus 40. [Oncogene 3, 151-158 \(1988\)](#).
34. S. Kraiss, A. Quaiser, M. Oren und M. Montenarh. Oligomerization of the oncoprotein p53. [J. Virol. 62, 4737-4744 \(1988\)](#).
35. M. Montenarh und A. Quaiser. Two different protein-protein interactions in oligomeric complexes of SV40 large T antigen with the cellular oncoprotein p53. [Oncogene 4, 379-382 \(1989\)](#).
36. G. Stetter und M. Montenarh. Complex interaction of SV40 large T antigen with the control region on the SV40 DNA. [Oncogene 4, 1353-1357 \(1989\)](#).
37. E. Reihnsaus, M. Kohler, S. Kraiss, M. Oren und M. Montenarh. Regulation of the level of the oncoprotein p53 in non-transformed and transformed cells. [Oncogene 5, 137-145 \(1990\)](#).
38. C. Buck und M. Montenarh. Platelet derived growth factor (PDGF). [Immun. Infekt. 18, 132-135 \(1990\)](#).
39. S. Kraiss, A. Barnekow und M. Montenarh. Protein kinase activity associated with immunopurified p53 protein. [Oncogene 5, 845-855 \(1990\)](#).
40. S. Kraiss, R. Espig, U. Vetter, W. Hartmann und M. Montenarh. Expression of p53 in human leukemic cell lines. [Leukemia Res. 14, 1041-1051 \(1990\)](#).
41. S. Kraiss, S. Spieß, E. Reihnsaus und M. Montenarh. Correlation between metabolic stabilization and altered quaternary structure of oncoprotein p53. [Exp. cell Res. 192, 157-164 \(1991\)](#).
42. G. Stetter, M. A. Braun und M. Montenarh. A new DNA binding assay to study subclasses of SV40 large T antigen binding to individual binding sites on the SV40 DNA. [Oncogene 6, 389-396 \(1991\)](#).
43. G. Stetter und M. Montenarh. Binding of subclasses of SV40 T antigen to separate binding regions of the SV40 DNA. *Virol. (Life Sci. Adv.)* 10, 29-41 (1991).
44. H. Seliger, A. Fröhlich, M. Montenarh, J. F. Ramalho Ortigao und H. Rösch. Oligonucleotide analogues with 3'-3' and 5'-5' internucleotide linkages as antisense inhibitors of viral replication. [Nucleosides, Nucleotides 10, 469-477 \(1991\)](#).
45. C. P. E. Herrmann, S. Kraiss und M. Montenarh. Casein kinase II is tightly associated with immunopurified p53. [Oncogene 6, 877-884 \(1991\)](#).
46. P. Schmid, A. Lorenz, H. Hameister und M. Montenarh. Expression of p53 during mouse embryogenesis. [Development 113, 857-865 \(1991\)](#).
47. H. Seliger, A. Fröhlich, G. Gröger, B. Krist, M. Montenarh, H. Rösch, R. Rösch und F. Ramalho Ortigao. Synthetic oligonucleotides for biomedical applications. *Nucl. Acid. Res. Sym. Ser.* 24, 193-196 (1991).
48. S. Kraiss, A. Lorenz und M. Montenarh. Protein-protein interactions in high molecular weight forms of the transformation-related phosphoprotein p53. [Biochim. Biophys. Acta 1119, 11-18 \(1992\)](#).
49. E. Reihnsaus, S. Kraiss, A. Barnekow und M. Montenarh. Cooperation of p53 and polyoma virus middle T antigen in the transformation of primary rat embryo fibroblasts. [Exp. Cell Res. 199, 10-18 \(1992\)](#).
50. J. F. Ramalho Ortigao, H. Rösch, H. Selter, A. Lorenz, M. Montenarh und H. Seliger. Antisense effect of oligodeoxynucleotides with inverted terminal internucleotidic linkages: A minimal modification protecting against nucleolytic degradation. [Antisense Res. Dev. 2: 129-146 \(1992\)](#).
51. M. Montenarh. Biochemical, immunological, and functional aspects of the growth-suppressor/ oncoprotein p53, p. 233-256. In [Critical Reviews in Oncogenesis](#). Vol. 3. CRC Press, Inc.,
52. A. Lorenz, C. P. E. Herrmann O.-G. Issinger und M. Montenarh. Phosphorylation of wild-type and mutant phenotypes of p53 by an associated protein kinase. *Int. J. Oncol.* 1: 571-579 (1992)
53. M. Montenarh. Biochemical properties of the growth suppressor/oncoprotein p53. [Oncogene 7, 1673-1680 \(1992\)](#).
54. M. Montenarh. Functional implications of the growth suppressor/oncoprotein p53. *Int. J. Oncol.* 1, 37-45 (1992)
55. G. V. Lopashov, H. Selter, M. Montenarh, W. Knöchel, H. Grunz, H. Tiedemann und H. Tiedemann. Neural inducing factors in neuroblastoma and retinoblastoma cell lines. [Naturwissenschaften 79, 365-367 \(1992\)](#).
56. H. Selter und M. Montenarh. Properties of a C-terminal polypeptide fragment of simian virus 40 large T antigen. *Int. J. Oncol.* 2, 837-845 (1993)
57. P. Lang, E.-D. Kreuser, J. Maurer, D. Höher, G. Bornhöft, M. Montenarh und E. Thiel. Mutation and expression of p53 tumor samples and cancer cell lines: Comparison of non-isotopic direct DNA-sequencing, immunoblotting and immunohistochemistry. *Int. J. Oncol.* 2, 347-355 (1993)

58. M.Hoeber, J.H.Clement, D. Wedlich, M.Montenarh und W.Knöchel. Overexpression of wild-type p53 interferes with normal development in *Xenopus laevis* embryos. [Oncogene 9, 109- 120 \(1994\)](#)
59. D. Höher, S.Kartarius, F.Porzolt und M.Montenarh. Immunologically defined subclasses of the growth suppressor protein p53 detected with antibodies in sera from tumor patients. *Int. J. Oncol.* 3, 741- 747 (1993)
60. H. Selter und M.Montenarh, The emerging picture of p53. [Int. J. Biochem. 26, 145- 154 \(1994\)](#)
61. P.Wagner, K.Appel, O.-G.Issinger und M.Montenarh, On the interaction of p53 with casein kinase II. *Int. J. Oncol.* 4, 491- 498 (1994)
62. M.Montenarh, C.P.E.Herrmann, D.Höher und H.Selter. Biochemical properties of p53 in a human tumor cell line. *Cancer Mol. Biol.* 1, 121- 131 (1994)
63. K.Appel, E.Schneider, P.Wagner and M.Montenarh, A new 42 KDa protein binding to the growth suppressor protein p53. *Int. J. Oncol.* 5, 667- 673, (1994)
64. D.Sturm and M.Montenarh, Expression of p53 after SV40 virus infection of quiescent cells. *Int. J. Oncol.* 5, 337-344, (1994)
65. U.Burk, H.Selter, Th.Zwergel, B.Wullich, M.Montenarh und G.Unteregger. Different subnuclear localization of wild-type and mutant p53 in human prostate cancer cells. *Int. J. Oncol.* 7, 1355- 1360 (1995)
66. F.Porzolt, M.Schmid, D.Höher, R.Muche, W.Gaus und M.Montenarh Biological relevance of auto-antibodies against p53 in patients with metastatic breast cancer. *Onkologie*, 17, 402- 408, (1994)
67. P.Wagner, M.Hoeber, K.Appel, W.Knöchel, und M.Montenarh. Fission yeast tms1 protein abrogates normal development in *Xenopus laevis* embryos. *Roux`s Archive Dev. Biol.* 204, 198- 202 (1995)
68. D.Sturm und M.Montenarh. Early response of quiescent cells to SV40 virus infection. *Int. J. Oncol.* 5, 1411- 1418 (1994).
69. P.Wagner, C.Waschow, W.Nastainczyk und M.Montenarh, New monoclonal antibodies against the tumor mutant suppressor tms1. [Hybridoma 13, 527- 529 \(1994\).](#)
70. M.Montenarh. Marker genes for cytotoxic exposure:p53. [Stem Cells 13, 136- 141 \(1995\).](#)
71. E.Schneider, A.Fuchs, W.Nastainczyk, M.Montenarh und P.Wagner. Precise epitope mapping of three monoclonal antibodies raised against tms1 protein of fission yeast. [Hybridoma 14, 329- 333 \(1995\).](#)
72. C.Götz und M.Montenarh. p53: DNA damage, DNA repair and apoptosis. [Rev. Physiol. Biochem. Pharm. 127, 65-95 \(1995\)](#)
73. C.Götz, M.Koenig, O.-G.Issinger und M.Montenarh. A protein kinase CK2 related kinase is tightly associated with SV40 large T antigen. [Eur. J. Biochem. 233, 327-334 \(1995\)](#)
74. H.Selter, S.Amela-Neuschwander, C.Villena-Heinsen und M. Montenarh. Antibodies against mdm2 in sera of patients with various gynaecological diseases. [Cancer Lett. 96, 111- 115 \(1995\)](#)
75. C.Götz und M.Montenarh. p53 and its implication in apoptosis. *Int.J.Oncol.* 6, 1129- 1135. (1995)
76. K.Appel, P.Wagner, B.Boldyreff, O.-G.Issinger und M.Montenarh. Mapping of the interaction sites of the growth suppressor protein p53 with the regulatory  $\beta$ -subunit of protein kinase CK2. [Oncogene 11, 1971- 1978 \(1995\)](#)
77. P.Wagner, A.Fuchs, A.Prowald, M.Montenarh und W.Nastainczyk. Precise mapping of the tms1 binding site on p53. [FEBS Lett. 377, 155- 158 \(1995\)](#)
78. C.Götz, P.Wagner, O.-G.Issinger und M.Montenarh p21WAF1/CIP1 interacts with protein kinase CK2. [Oncogene 13, 391- 398 \(1996\)](#)
79. M.G.Koenig, D.Sturm, O.-G.Issinger, und M.Montenarh. Interaction of p53 with protein kinase CK2 during SV40 induced entrance of quiescent cells into the cell cycle. *Int. J. Oncol.* 10, 405-411 (1997)
80. M.Hoeber, C.P.E.Herrmann und M.Montenarh. Biochemical properties of *Xenopus laevis* p53. *Int. J. Oncol.* 10, 195- 203 (1997)
81. B.Guerra, C.Götz, Wagner,P., M.Montenarh und O.-G.Issinger. The carboxy terminus of p53 mimicks the polylysine effect of protein kinase CK2-catalyzed MDM2 phosphorylation. [Oncogene 14, 2683- 2688 \(1997\)](#)
82. A.Prowald, N.Schuster und M.Montenarh. Regulation of the DNA binding activity of p53 by its interaction with protein kinase CK2. [FEBS Lett. 408, 99- 104 \(1997\)](#)
83. A.Nickels, M.Bureik, M.Montenarh, M.Pfreundschuh und B.Koch. p53 antibodies: a call for quality. [Int. J. Cancer 73, 613- 614 \(1997\)](#)
84. A.Nickels, H.Selter, M.Montenarh, M. Pfreundschuh und B.Koch. Detection of p53 in inflammatory tissue and in lymphocytes by immunohistology and flow cytometry- a critical comment. [J. Clinical Pathol. 50, 654- 660 \(1997\)](#)
85. M.Montenarh. Das Wachstumssuppressorprotein p53, seine zellulären Partner und das Prostatacarcinom. *Akt. Urol.* 28, 371- 376 (1997).
86. M.Montenarh und C.Götz. p53 autoantibodies and human malignancy. *Cancer Molec. Biol.* 4, 991- 1010 (1997)
87. M.Montenarh und C.Götz. p53 Autoantikörper in der Tumordiagnostik. *Münch. med. Wschr.* 139, 673- 674 (1997)

88. P.Wagner, A.Fuchs, W.Nastainczyk, C. Götz und M.Montenarh. Fine mapping and regulation of the association of p53 and p34cdc2. [Oncogene 16, 105-111 \(1998\)](#)
- 89.N.Rief, C.Waschow, W.Nastainczyk, M.Montenarh und C.Götz. Production and characterization of a rabbit monoclonal antibody against human CDC25C phosphatase.[Hybridoma 17: 389-394 \(1998\)](#)
90. C.Götz, S.Kartarius, P.Scholtes und M.Montenarh. *In vitro* studies of the interaction between protein kinase CK2 and p21WAF1/CIP1. *Cancer Molec. Biol.* 5, 1189- 1205 (1998)
91. C.Lang, G.Unteregger, S.Kartarius, J.Günther, H.Bonkhoff, M.Montenarh und T.Zwergel. p53 autoantibodies in patients with urological tumors. [Br. J. Urol. 82, 721- 725 \(1998\)](#)
- 92.M.Montenarh. Humoral response against p53 in human malignancies. In *Pathogenic and diagnostic relevance of autoantibodies*. Ed. K. Conrad, R.-L. Humbel, M. Meurer, Y. Shoenfeld und E. M. Tan. Pabst Science Publishers, Lengerich, Berlin, Düsseldorf 377- 394 (1998)
93. R.Hallak, J.Mueller, O.Lotter, S.Gansauge, F.Gansauge, M.E.-D.Jumma, M.Montenarh, F.Safi und H.Beger. p53 genetic alterations, protein expression and autoantibodies in human colorectal carcinoma: A comparative study. [Int. J. Oncol. 12, 785- 791 \(1998\)](#)
94. M.Montenarh, A.Harlozinska, J.K. Bar, S. Kartarius, J. Günther und P.Sedlaczek. p53 autoantibodies in the sera and ascites fluids with ovarian cancer. [Int. J. Oncol. 13, 605- 610 \(1998\)](#)
95. E.Schneider, M.Montenarh und P.Wagner. Regulation of CAK kinase activity by p53. [Oncogene 17, 2733- 2742 \(1998\)](#)
96. H.Selter, G.Schmidt, C.Villena-Heinsen und M.Montenarh. Humoral immune response to p21WAF1/CIP1 in tumor patients, non-tumorous patients and healthy blood donors. [Cancer Lett. 137, 151- 157 \(1999\)](#)
- 97.J.Benninghoff, Z.Teleb, H.Selter, G.Unteregger, T.Zwergel, B.Wullich und M.Montenarh. Two different forms of p53 localized differently within cells of urogenithial tumors. [Cancer Letters 144, 55-64 \(1999\)](#)
98. C.Götz, P.Scholtes, N.Schuster, A.Prowald, W.Nastainczyk und M.Montenarh. Protein kinase CK2 binds to a multi-protein binding domain of the growth suppressor protein p53. [Mol. Cell. Biochem. 191, 111- 120 \(1999\)](#)
- 99.N.Schuster, A.Prowald, E.Schneider, K.-H.Scheidtmann und M.Montenarh. Regulation of p53 mediated transactivation by the  $\beta$ - subunit of protein kinase CK2. [FEBS Letters 447, 160- 166 \(1999\)](#)
100. C.Götz, S.Kartarius, P.Scholtes, W.Nastainczyk, und M.Montenarh. Identification of a CK2 phosphorylation site in mdm2. [Eur. J. Biochem. 266, 493- 501 \(1999\)](#)
101. M.Faust, N.Schuster und M.Montenarh. Specific binding of protein kinase CK2 catalytic subunits to tubulin. [FEBS Letters 462, 51-56 \(1999\)](#)
102. M.Montenarh. Humoral immune response against the growth suppressor p53 in human malignancies. In: *Cancer and Autoimmunity*. 193- 203 Eds: Y.Schoenfeld and M. E. Gershwin, Elsevier Amsterdam, (2000)
103. C.Götz, S. Kartarius, P. Scholtes und M.Montenarh. Binding domain for 21WAF1/CIP1 on the polypeptide chain of the protein kinase CK2 beta-subunit. [Biochem. Biophys. Res. Commun. 268, 882- 885 \(2000\)](#)
104. A.Harlozinska, J.Bar und M.Montenarh. Analysis of the immunoreactivity of three anti-p53 antibodies and estimation of the relations between p53 status and mdm2 protein expression in ovarian carcinomas. *Anticancer Res.* [20\(2A\):1049-56 \(2000\)](#)
105. U.Mack,D.Ukena,M.Montenarh und G.Sybrecht. Serum anti p53 antibodies in patients with lung cancer. [Oncology Rep. 7, 669- 974, \(2000\)](#)
106. M.Montenarh. p53 Autoantikörper in der klinischen Diagnostik. [Deutsche Medizinische Wochenschrift 125, 941- 943 \(2000\)](#)
107. N.Rief, H.Herges, A.Prowald, C.Götz und M.Montenarh. Binding of the growth suppressor p53 protein to the cell cycle regulator phosphatase cdc25C. [Int.J.Oncol. 17, 186- 195 \(2000\)](#)
108. M.Faust und M.Montenarh. Subcellular localization of protein kinase CK2: A key to its function? [Cell Tissue Res. 301, 329- 340 \(2000\)](#)
109. M.Bureik, N.Rief, R.Drescher, A.Jungbluth, M. Montenarh und P.Wagner. An additional transcript of the cdc25C gene from A431 cells encodes a functional protein. [Int. J. Oncol. 17, 1251- 1258, \(2000\)](#)
110. N.Schuster, C.Götz, M.Faust, E.Schneider, A.Prowald, A. Jungbluth und M. Montenarh. Wild- type p53 inhibits protein kinase CK2 activity. [J. Cell. Biochem. 81, 172- 183 \(2001\),](#)
111. M.Ababneh, C.Götz und M.Montenarh. Downregulation of the cdc2/cyclin B protein kinase activity by binding of p53 to p34cdc2. [Biochemical and Biophysical Research Communications 283, 507-512 \(2001\)](#)
112. M.Faust, M.Jung, J.Günther, R.Zimmermann und M.Montenarh. Localization of individual subunits of protein kinase CK2 to the endoplasmic reticulum and to the Golgi apparatus. [Mol. Cell. Biochem. 227, 73- 80 \(2001\)](#)
113. S.L.Schwindling, M.Faust, M.Montenarh. Determination of the mitotic index by microinjection of fluorescently labelled tubulin. [Eur. J. Cell Biol. 81, 169- 174 \(2002\)](#)
114. A.Harlozinska, J.K.Bar, M.Montenarh und S.Kartarius. Relations between immunologically different p53 forms, p21<sup>WAF1</sup> and PCNA expression in ovarian carcinomas. [Oncology Rep. 9 1173- 1180 \(2002\)](#)

115. E.Schneider, S.Kartarius, N.Schuster und M. Montenarh. The cyclin H/cdk7/Mat1 kinase activity is regulated by CK2 phosphorylation of cyclin H. [Oncogene 21, 5031-5037 \(2002\)](#)
116. M.Faust, S.Kartarius, S.L.Schwindling und M.Montenarh. Cyclin H is a new binding partner for protein kinase CK2. [Biochem. Biophys. Res. Commun. 296, 6- 12 \(2002\)](#)
117. J.Bar, A.Harlozinska, S.Kartarius, M.Montenarh, E.Wyrodek, J.M.R.Parkitna, M.Kochman, A.Ozyhar. Temperature-sensitive ovarian carcinoma cell line (OvBH-1). [Jap.J.Cancer Res. 93, 976-985 \(2002\)](#)
118. M.Faust, J.Günther, E. Morgenstern, M. Montenarh und C. Götz. Specific localization of the catalytic subunits of protein kinase CK2 at the centrosomes. [Cell. Mol. Life Sci. 59, 2155- 2164 \(2002\)](#)
119. J.Saleh und M.Montenarh. p53 autoantibodies in the sera of patients with various types of malignancies. Arab J. Pharmaceutical Sciences 2, 63-72 (2003)
120. M.Montenarh. Protein kinase CK2: in search for its regulation. Advances in Clinical and Experimental Medicine 12, 15- 22 (2003)
121. A.Hessenauer, M.Montenarh und C.Götz. Inhibition of CK2 activity provokes different responses in hormone- sensitive and hormone-refractory prostate cancer cells. [Int. J. Oncol. 22, 1263- 1270 \(2003\)](#)
122. S.Facchin, R.Lopreiato, M.Ruzzene, O.Marin, C.Götz, G.Sartori, M.Montenarh, G.Carignani, und L.A.Pinna. Functional conservation within a primordial protein kinase family: yeast piD/Bud32 and human PRPK display interchangeable roles. [FEBS Letters 549, 63- 66 \(2003\)](#)
123. M.Montenarh. Prognostische Bedeutung immunhistochemischer Untersuchungen. [HNO 51, 787- 789 \(2003\)](#)
124. S.L.Schwindling, A.Noll, M.Montenarh und C.Götz. Mutation of the CK2 phosphorylation site in cdc25C impairs importin a/b binding and results in cytoplasmic retention. [Oncogene 23, 4155- 4165 \(2004\)](#)
125. A.Ibrahim, J.Saleh, M.Montenarh, M.Juma und M.Obeid. Serum anti-p53 antibodies in patients with atherosclerosis. Arab J. Pharmaceutical Sciences 2, 63- 68 (2004)
126. J.Saleh, D. Kreissler-Haag und M. Montenarh. p53 autoantibodies from patients with colorectal cancer recognize common epitopes in the N- and C- terminus of p53. [Int. J. Oncol. 25, 1149- 1156 \(2004\)](#)
127. B.Schick, B. Veldung, S. Wemmert, V. Jung, M. Montenarh, E. Meese, und S. Urbschat. p53 and Her-2/neu in juvenile angiofibromas. [Oncology Reports 13, 453- 458 \(2005\)](#)
128. C.Götz, S.Kartarius, G.Schwär und M.Montenarh. Phosphorylation of mdm2 at serine 269 impairs its interaction with the retinoblastoma protein. [Int. J. Oncol. 26, 801- 808 \(2005\)](#)
129. M.Bureik, A.Zöllner, N.Schuster, M.Montenarh und R.Bernhardt. Phosphorylation of bovine adrenodoxin by protein kinase CK2 affects the interaction with the redox partner cytochrome P450 scc (CYP11A1). [Biochemistry 44, 3821-3830 \(2005\)](#)
130. Götz, C., Kartarius, S., Schetting, S. und Montenarh, M. Immunologically defined subclasses of the protein kinase CK2 $\beta$ -subunit in prostate carcinoma cell lines. [Mol. Cell. Biochem. 274: 181-187, \(2005\).](#)
131. Klein, A., Jung, V., Zang, K.D., Henn, W., Montenarh, M., Kartarius, S. und Urbschat, S. Detailed chromosomal characterization of the breast cancer cell line MCF7 with special focus on the expression of the serine-threonine kinase 15. [Oncol. Rep. 14: 23-31, \(2005\).](#)
132. Krempler, A., Kartarius, S., Günther, J. und Montenarh, M. Cyclin H is targeted to the nucleus by C-terminal nuclear localization sequences. [Cell. Mol. Life Sci. 62: 1379-1387, \(2005\).](#)
133. Montenarh M. in: p53 autoantibodies in the diagnosis and prognosis of tumors. p. 92-107. Conrad K, Bachmann M, Lehmann W, Sack U, editors. Methods, possibilities and perspectives in pre-symptomatic tumor diagnosis. Lengerich, Berlin, Bremen, Miami, Riga, Viernheim, Wien, Zagreb: Pabst Science Publishers, (2005).
134. Schlade-Bartusiak, K., Sasiadek, M.M., Bar, J.K., Urbschat, S., Blin, N., Montenarh, M. und Harlozinska-Szmyrka, A. Cytogenetic and molecular cytogenetic characterisation of the stable ovarian carcinoma cell line (OvBH-1). [Cancer Genet. Cytogenet. 164: 10-15, \(2006\).](#)
135. Saleh, J., Brunner, C., Gölzer, R., Nastainczyk, W. und Montenarh, M. p53 autoantibodies from patients with head and neck cancer recognize common epitopes on the polypeptide chain of p53. [Cancer Lett. 233: 48-56, \(2006\).](#)
136. Schick, B., Wemmert, S., Jung, V., Steudel, W.I., Montenarh, M. und Urbschat, S. Genetic heterogeneity of the MYC oncogene in advanced juvenile angiofibromas. [Cancer Genet. Cytogenet. 164: 25-31, \(2006\).](#)
137. Bachmann, M., Kosan, C., Xiang, P.X., Montenarh, M., Hoffmann, I. und Möröy, T. The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates G2/M specific phosphatase Cdc25C. [Int. J. Biochem. Cell Biol. 38 \(3\): 430-443, \(2006\).](#)
138. Kramerov, A.A., Saghizadeh, M, Pan, H., Kabosova, A., Montenarh, M., Ahemd, K., Penn, J.S., Chan, C.K., Hinton, D.R., Grant, M.B. und Ljubimov, A.V., Expression of Protein kinase CK2 in Astroglial Cells of normal and neovascularized Retina, [Am. J. Pathol. 168 \(5\), 1722-1736, \(2006\)](#)
139. Touma, R., Kartarius, S., Harlozinska, A. Götz, C. und Montenarh, M. Growth inhibition and apoptosis induction in ovarian cancer cells. [Int. J. Oncol. 29, 481- 488 \(2006\)](#)
140. Noll, A., Ruppenthal, S. und Montenarh, M. The mitotic phosphatase cdc25C at the Golgi apparatus. [Biochem. Biophys. Res. Commun. 351: 825-830 \(2006\)](#)

141. Götz,C., Bachmann,C. und Montenarh,M. Inhibition of protein kinase CK2 leads to a modulation of androgen receptor dependent transcription in prostate cancer cells. [The Prostate 67: 125- 134 \(2007\)](#)
142. Ruppenthal,S.L., Noll,A., Götz,C. und Montenarh,M. Interference between p53 and cdc25C in cell cycle regulation. [Int. J. Oncol. 31, 345-362 \(2007\)](#)
143. Busch,C., Barton,O., Morgenstern,E., Günther,J., Noll,A., Götz,C. und Montenarh,M. Protein phosphatase cdc25C is located within centrosomes. [Int. J. Biochem. Cell Biol. 39, 1707- 1713 \(2007\)](#)
144. Prowald,A., Cronauer,M.V., von Klot,C., Eilers,T.,Rinnab,L., Herrmann,T, Spindler,K.D., Montenarh,M.,Jonas,U., Burchardt,M. Modulation of  $\beta$ -catenin-mediated TCF-signalling in prostate cancer cell lines by wild-type and mutant p53. [The Prostate 67, 1751- 1760 \(2007\)](#)
145. Lehnert,S., Götz,C., Kartarius,S., Schäfer,B. und Montenarh,M. Protein kinase CK2 interacts with the splicing factor hPrp3p. [Oncogene 27, 2390 - 2400 \(2008\)](#)
146. Al-Quobaili,F. und Montenarh,M. Pancreatic duodenal homeobox factor-1 and diabetes mellitus type 2. [Int. J. Mol. Medicine 21, 399-404 \(2008\)](#)
147. Touma,R. und Montenarh,M. Laboratory study of the cdc25C enzymatic activity in ovarian cancer. *J. Clin. Lab.* 4, 9- 18 (2008)
148. Dörr,J., Kartarius,S., Götz,C. und Montenarh, M. Contribution of the individual subunits of protein kinase CK2 and of hPrp3p to the splicing process. [Mol. Cell. Biochem. 316, 187- 193 \(2008\)](#)
149. Kramerov,A.A., Saghizadeh,M., Caballero,S., Shaw,L.C., Li Calzi,S., Bretner,M., Montenarh,M., Pinna,L.A., Grant,M.B. und Ljubimov,A.V. Inhibition of protein kinase CK2 suppresses angiogenesis and hematopoietic stem cell recruitment to retinal neovascularization sites. [Mol. Cell. Biochem. 316, 177- 186 \(2008\)](#)
150. Schäfer,B., Götz,C. und Montenarh,M. The kinesin I family member KIF5C is a new substrate for protein kinase CK2. *Biochem. Biophys. Res. Commun.* 375, 179- 183 (2008)
151. Schäfer,B., Götz,C., Dudek, J., Hessenauer, A., Matti, U. und Montenarh, M. KIF5C: a new binding partner for protein kinase CK2 with a preference for the CK2 $\alpha$ ' subunit. [Cell. Mol. Life Sci. 66, 339- 349 \(2009\)](#)
152. Schneider,C.C., Hessenauer,A., Götz,C. und Montenarh,M. DMAT, an inhibitor of protein kinase CK2 induces reactive oxygen species and DNA double strand breaks. [Oncology Rep. 21, 1593- 1597 \(2009\)](#)
153. Cerella,C., Scherer,C., Cristofanon,S., Henry,E., Anwar,A., Busch,C., Montenarh,M., Dicato,M., Jacob,C. und Diederich,M. Cell cycle arrest in early mitosis and induction of caspase-dependent apoptosis in U937 cells by diallyltetrasulfide (Al2S4). *Apoptosis.* 14, 641- 647 (2009)
154. Götz,C., Müller,A., Montenarh,M., Zimmermann,R. und Dudek,J. The ER-membrane-resident Hsp40 ERj1 is a novel substrate for protein kinase CK2. [Biochem. Biophys. Res. Commun. 388, 637- 642 \(2009\)](#)
155. Schneider,C.C., Hessenauer,A., Montenarh,M., und Götz,C. p53 is dispensable for the induction of apoptosis after inhibition of protein kinase CK2. [The Prostate 70, 126- 134 \(2010\)](#)
156. Busch, C., Jacob, C., Anwar, A., Burkholz, T., Aicha Ba, L., Cerella, C., Diederich, M., Brandt, W., Wessjohann, L. und Montenarh, M. Diallylpolysulfides induce growth arrest and apoptosis. [Int. J. Oncol. 36, 743- 749 \(2010\)](#)
157. Meng, R., Al-Quobaili, F., Müller, I., Götz, C., Thiel, G. und Montenarh, M. CK2 phosphorylation of Pdx-1 regulates its transcription factor activity. [Cell. Mol. Life Sci. 67, 2481-2489\(2010\)](#)
158. Mannowetz,N., Kartarius,S., Wennemuth,G. und Montenarh,M. Protein kinase CK2 and new binding partners during spermatogenesis. [Cell. Mol. Life Sci. 67, 3905- 3913 \(2010\)](#)
159. Ampofo,E., Kietzmann,T., Zimmer,A., Jakupovic,M., Montenarh,M. und Götz,C. Phosphorylation of the von Hippel-Lindau protein (VHL) by protein kinase CK2 reduces its protein stability and affects p53 and HIF-1 $\alpha$  mediated transcription. [Int. J. Biochem. Cell Biol. 42, 1729-1735 \(2010\)](#)
160. Hessenauer,A., Schneider,C.C., Götz,C. und Montenarh, M. CK2 inhibition induces apoptosis via the ER stress response. [Cellular Signaling 23, 145- 151 \(2011\)](#)
161. Hammadeh,M.E., Hamad,M.F., Montenarh,M. und Fischer-Hammadeh,C. Protamine contents and P1/P2 ratio in human spermatozoa from smokers and non-smokers. [Human Reproduction 25, 2708- 2720 \(2010\)](#)
162. Meng,R., Götz,C. und Montenarh,M. The role of protein kinase CK2 in the regulation of the insulin production of pancreatic islets. [Biochem. Biophys. Res. Commun. 401, 203- 206 \(2010\)](#)
163. Montenarh,M. Cellular regulators of protein kinase CK2. [Cell and Tissue Res. 342, 139- 146 \(2010\)](#)
164. Olsen,B.B., Fischer,U., Rasmussen,R.L., Montenarh,M., Meese,E., Fritz,G., Issinger,O.G. Lack of the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) is accompanied by increased CK2 $\alpha$ ' levels. [Mol.Cell.Biochem. 356, 139- 147 \(2011\)](#)
165. Schneider,C.C., Götz,C., Hessenauer,A., Günther,J., Kartarius,S., Montenarh,M. Down-regulation of CK2 activity results in a decrease in the level of cdc25C phosphatase in different prostate cancer cell lines. [Mol.Cell.Biochem. 356, 177-184 \(2011\)](#)
166. Montenarh,M. Diallyl sulfides and the decision about life and death of a cell. p 329-344, in "Natural compounds as inducers of cell death: Volume I" eds. M. Diederich und K. Noworyta, Springer Science+Business Media, Dordrecht, (2012)

167. Jacob,C., Burkholz,T., Du,P., Battaglia,E., Bagrel,D. und Montenarh,M. Control of oxidative posttranslational cysteine modifications: From intricate chemistry to widespread biological and medical applications. [Chem.Res.Toxicol. 25, 588- 604 \(2012\)](#)
168. Montenarh,M. und Saidu,N.E.B. The effect of diallyl polysulfanes on cellular signaling cascades. [Nat. Product Commun. 7, 401- 408 \(2012\)](#)
169. Essa,S., Reichrath,S., Mahlknecht,U., Montenarh,M., Vogt,T. und Reichrath,J. Signature of VDR miRNAs and epigenetic modulation of vitamin D signaling in melanoma cell lines. [Anticancer Research 32, 383- 389 \(2012\)](#)
170. Saidu,N.E.B., Valente,S.,Bana,E., Kirsch,G., Bagrel,D. und Montenarh,M. Coumarin polysulfides inhibit cell growth and induce apoptosis in HCT116 colon cancer cells. [Bioorganic & Medicinal Chemistry 20, 1584- 1593 \(2012\)](#)
171. Wilhelm,N., Kostelnik,K., Götz,C. und Montenarh,M. Protein kinase CK2 is implicated in early steps of the differentiation of pre- adipocytes into adipocytes. [Mol. Cell. Biochem. 365, 37-45 \(2012\)](#)
172. Feng,D., Welker,S., Körbel,C., Rudzitis-Auth,J., Menger,M.D., Montenarh,M. und Laschke, M. Protein kinase CK2 is a regulator of angiogenesis in endometriotic lesions. [Angiogenesis 15, 243-252 \(2012\)](#)
173. Schneider,C.C., Ampofo,E. und Montenarh,M. CK2 regulates ATF4 and CHOP transcription within the cellular stress response signaling pathway. [Cellular signaling 24, 1797- 1802 \(2012\)](#)
174. Schneider,C.C., Kartarius,S., Montenarh,M. Oreszko,A. und Kazimierzczuk,Z. Modified tetrahalogenated benzimidazols with CK2 inhibitory activity are active against human prostate cancer cells LNCaP *in vitro*. [Bioorganic and Medicinal Chemistry 20, 4390- \(4396 \(2012\)](#)
175. Al-Quobaili,F. und Montenarh,M. CK2 and the regulation of the carbohydrate metabolism. [Metabolism 61, 1512-1517 \(2012\)](#)
176. Montenarh,M. und Götz,C. The interactome of protein kinase CK2. pp 76- 116, in Protein Kinase CK2, Ed. Lorenzo A. Pinna, John Wiley & Sons, Inc. (2013)
177. Saidu,N.E.B., Touma,R., Abu Asali,I., Jacob,C. und Montenarh,M. Diallyl tetrasulfane activates both the eIF2 $\alpha$  and Nrf2/HO-1 pathways. [Biochim. Biophys. Acta 1830, 2214- 2225 \(2013\)](#)
178. Ampofo,E., Sokolowsky,T., Götz,C. und Montenarh,M. Functional interaction of protein kinase CK2 and activating transcription factor 4 (ATF4), a key player in the cellular stress response. [Biochim. Biophys. Acta Mol. Cell. Res. 1833, 439- 451 \(2013\)](#)
179. Ampofo,E., Welker,S., Jung,M., Müller,L., Greiner,M., Zimmermann,R. und Montenarh,M. CK2 phosphorylation of human Sec63 regulates its interaction with Sec62. [Biochim. Biophys. Acta 1830, 2938- 2945 \(2013\)](#)
180. Götz,C. und Montenarh,M. Protein kinase CK2 in the ER stress response. [Ad. Biol. Chem. 3, 1- 5 \(2013\)](#)
181. Saidu,N.E.B., Abu Asali,I., Czepukojc,B., Seitz,B., Jacob,C. und Montenarh,M. Comparison between the effects of diallyl tetrasulfide on human retina pigment epithelial cells (ARPE-19) and HCT116 cells. [Biochim. Biophys. Acta 1830, 5267- 5276 \(2013\)](#)
182. Lupp,S., Gumhold,C., Ampofo,E., Montenarh,M. und Rother,K. CK2 kinase activity but not its binding to CK2 promoter regions is implicated in the regulation of CK2 $\alpha$  and CK2 $\beta$  gene expression. [Mol. Cell. Biochem. 384, 71- 82 \(2013\)](#)
183. Welker,S., Götz,C., Servas,C., Laschke,M.W., Menger,M.D. und Montenarh,M. Glucose regulates protein kinase CK2 in pancreatic  $\beta$ -cells and its interaction with PDX-1. [The International Journal of Biochemistry & Cell Biology 45, 2786- 2795 \(2013\)](#)
184. Du,P., Viswanathan,U., Kairan,K., Buric,T., Saidu,N.E.B., Xu,Z., Hanf,B., Bazukyan,I., Trchounian,A., Hannemann,F., Bernhardt,I., Burkholz,T., Disel,B., Kierner,A., Schäfer,K.H., Montenarh,M., Kirsch,G., Jacob,C. Synthesis of amphiphilic, chalcogen-based redox modulators with *in vitro* cytotoxic activity against cancer cells, macrophages and microbes. [MedChemComm 5, 25-31 \(2014\)](#)
185. Cepukojc,B., Baltas,A.K., Cerella,C., Kelkel,M., Viswanathan,U.M., Salm, F., Burkholz,T., Schneider,C., Dicato,M., Montenarh,M., Jacob,C., Diederich,M. Synthetic polysulfane derivatives induce cell cycle arrest and apoptotic cell death in human hematopoietic cancer cells. [Food Chem. Toxicol. 64, 249- 257 \(2014\)](#)
186. Du,P., Saidu,N.E.B., Intemann,J., Jacob,C. und Montenarh,M. A new tellurium-containing amphiphilic molecule induces apoptosis in HCT116 colon cancer cells [Biochim. Biophys. Acta 1840, 1808- 1816 \(2014\)](#)
187. Montenarh,M. Protein kinase CK2 and angiogenesis. [Advances in Clinical and Experimental Medicine 23, 153- 158 \(2014\)](#)
188. Intemann,J. Saidu,N.E.B., Schwind,L. und Montenarh,M. ER stress signaling in ARPE-19 cells after inhibition of protein kinase CK2 by CX-4945. [Cell Signaling 26, 1567- 1575 \(2014\)](#)
189. Hamad,M., Shelko,N., Kartarius,S., Montenarh,M. und Hammad,M.E. Impact of cigarette smoking on histone (H2B) to protamine ratio in human spermatozoa and its relation to sperm Parameters. [Andrology 2, 666- 677 \(2014\)](#)
190. Welker,S., Servas,C., Meng,R. Götz,C. und Montenarh,M. Tissue specific functions and regulation of protein kinase CK2. in Protein kinase CK2 cellular function in normal and disease states. eds Ahmed,K., Issinger,O.G. und Szyszka,R. Springer 109- 123 (2015)
191. Lupp,S., Götz,C., Khadouma,S., Horbach,T., Dimova,E.Y., Bohrer, A.-M., Kietzmann,T. und Montenarh,M. The upstream stimulatory factor USF1 is regulated by protein kinase CK2 phosphorylation. [Cell Signaling 26, 2809- 2817 \(2014\)](#)
192. Schwind,L., Zimmer,A.D., Götz,C. und Montenarh,M. CK2 phosphorylation of C/EBP $\delta$  regulates its transcription factor activity. [Int. J. Biochem. Cell. Biol. 61, 81- 89 \(2015\)](#)
193. Schwind,L., Wilhelm,N., Kartarius,S., Montenarh,M., Gorjub,E. und Götz,C. Protein kinase CK2 is necessary for the differentiation of human mesenchymal stem cells. [Biochim. Biophys. Acta 1853, 2207- 2216 \(2015\)](#)

194. Rezk Allah,D., Schwind,L., Abu Asali,I., Nasim, J., Jacob,C., Götz,C. und Montenarh,M. A scent of therapy: Synthetic polysulfanes with improved physico-chemical properties induce apoptosis in human cancer cells. [Int. J. Oncol. 47, 991-1000 \(2015\)](#)
195. Ampofo,E., Rudzitis-Auth,J., Dahmke,I.N., Rössler,O., Thiel,G., Montenarh,M., Menger,M.D. und Laschke,M.W. Inhibition of protein kinase CK2 suppresses tumor necrosis factor (TNF $\alpha$ ) induced leukocyte-endothelial cell interaction. [Biochim. Biophys. Acta Molecular Basis of Disease 1852, 2123- 2136 \(2015\)](#)
196. Ampofo,E., Müller,I., Dahmke,I.N., Eichler,H., Montenarh,M., Menger,M.D. und Laschke,M. Role of protein kinase CK2 in the dynamic interaction of platelets, leukocytes and endothelial cells during thrombus formation. [Thrombosis Research 136, 996- 1006 \(2015\)](#)
197. Spohrer,S., Dimova, E.Y., Kietzmann,T., Montenarh,M. und Götz,C. The nuclear fraction of protein kinase CK2 binds to the upstream stimulatory factors (USFs) in the absence of DNA. [Cell signalling 28, 23- 31 \(2016\)](#)
198. Montenarh,M. Protein Kinase CK2 in DNA damage and repair. [Translational Cancer Research 5, 49- 63 \(2016\)](#)
199. Shelko,N., Hamad,M.F., Montenarh,M. und Hammadeh,M.E. The Influence of cigarette smoking on sperm quality and sperm membrane integrity. [Current Women's Health Review 12, 58- 65 \(2016\)](#)
200. Ampofo,E., Widmaier,D., Montenarh,M., Menger,M. und Laschke,M. Protein kinase CK2 regulates leukocyte-endothelial cell interactions during ischemia and reperfusion. [European Surgical Research 57, 111- 124 \(2016\)](#)
201. Hammadeh,E.M., Amor,H. und Montenarh,M. Cigarette Smoking and structural, biochemical functional alterations of spermatozoa and their consequences for ART. Austin [J In Vitro Fertil. 3, \(1\) 1027 \(2016\)](#)
202. Faulstich,L., Griffin,S., Nasim,M.J., Masood,M.I., Ali,W., Alhamound,S., Omram,Y., Kim,H., Kharma,A., Schäfer,K.H., Lilischkis,R., Montenarh,M., Keck,C. und Jacob,C. Nature's Hat-trick:Can we use sulfur springs as ecological source for materials with agricultural and medical applications? [Int. J. Biodeterioration and Biodegradation 119, 678-686 \(2017\)](#)
203. Götz,C. und Montenarh,M. Protein kinase CK2 in development and differentiation [Biomed. Rep. 6: 127- 133 \(2017\)](#)
204. Klein,S., Meng,R. Montenarh, M. und Götz,C. The phosphorylation of PDX-1 by protein kinase CK2 is crucial for its stability. [Pharmaceuticals 10, E2 \(2016\)](#)
205. Schwind,L., Schetting,S. und Montenarh,M. Inhibition of protein kinase CK2 prevents adipogenic differentiation in mesenchymal stem cells like C3H10T1/2 cells. [Pharmaceuticals 10, E22 \(2017\)](#)
206. Jose,J., Le-Borgne, M., Pinna,L. und Montenarh, M. An updated view on an emerging target: Selected papers from the 8th International Conference on Protein Kinase CK2. [Pharmaceuticals 10, E33 \(2017\)](#)
207. Zwergel,C., Czepukojc,B., Evan-Bana,E., Xu,Z., Stazi,G., Mori,M., Patsilnakos,A., Mai, A., Botta,B., Ragno,R., Bagrel,D., Kirsch,G., Meiser,P., Jacob,C.,Montenarh,M. und Valente,S. Novel coumarin- and quinoline-based polycycles as cell Division cycle 25-A and -C phosphatases Inhibitors induce Proliferation Arrest and apoptosis in cancer cells. [Eur. J. Med. Chem. 134, 316- 333 \(2017\)](#)
208. Servas,C., Kiehlmeier,S., Hach,J., Gross,R., Götz,C. und Montenarh,M. The mammalian STE20-like kinase 1 (MST1) is a substrate for the apoptosis inhibiting protein kinase CK2. [Cell Signalling 36, 163- 175 \(2017\)](#)
209. Bender,M., Schwind,L., Grundmann,D., Klotz,M., Götz,C., Montenarh,M. und Schäfer K.H. Impact of protein kinase CK2 inhibitors on proliferation and differentiation of neural stem cells. [Heliyon 2, e00318 \(2017\)](#)
210. Schwind,L., Nalbach,L., Zimmer,A.D., Kostelnik,K., Menegatti,J., Grässer,F., Götz,C. und Montenarh,M. Quinalizarin inhibits adipogenesis through down-regulation of transcription factors and microRNA modulation. [Biochim. Biophys. Acta General Subjects 1861, 3272- 3281 \(2017\)](#)
211. Hamad,M., Shelko,N., Montenarh,M. und Hammadeh,M.E. The Impact of cigarette Smoking on protamines 1 and 2 transcripts in human spermatozoa. [Human Fertility 2017, 1-7 \(2017\)](#)
212. Spohrer,S., Gross,R., Nalbach,L., Schwind,L., Stumpf,H., Menger,M.D., Ampofo,E., Montenarh,M. und Götz,C. Functional interplay between the transcription factors USF1 and PDX-1 and protein kinase CK2 in pancreatic beta cells. [Sci. Rep. 7, 16367 \(2017\)](#)
213. Montenarh,M. und Götz,C. Ecto-protein kinase CK2, the neglected form of CK2. [Biomed. Reports 8, 307-313 \(2018\)](#)
214. Hamad,M.F., Abu Dayyih,W.A., Laqqan,M., Alkaled,Y., Montenarh,M. und Hammadeh,M.E. The status of global DNA methylation in the spermatozoa of smokers and non-smokers. [Reprod. Biomed. Online 37, 581-589 \(2018\)](#)
215. Alshawa,E., Laqqan,M. Montenarh,M. und Hammadeh,M.E. Influence of cryopreservation on the CATSPER2 and TEKT2 Expression Levels and Protein Levels in human spermatozoa. [Toxicology Reports 2019, 819-824 \(2019\)](#)
216. Ampofo,E., Nalbach,L.,Menger,M.D., Montenarh,M. und Götz,C. Protein kinase CK2- A putative target for the therapy of Diabetes mellitus. [Int. J. Mol. Sci. 20, E4398 \(2019\)](#)
217. Schmitt,B.M., Ampofo,E., Stumpf,H., Montenarh,M. und Götz,C. The stability of CREB3/Luman is regulated by protein kinase CK2 phosphorylation. [Biochem. Biophys. Res. Commun. 523, 639- 644 \(2020\).](#)
218. Scheuer,R., Philipp,S.E., Becker,A.,Nalbach,L.,Ampofo,E.,Montenarh,M. und Götz,C. Protein kinase CK2 controls Ca<sub>v</sub>2.1-dependent calcium currents and insulin release in pancreatic beta-cells. [Int. J. Mol. Sci. 21, 4668 \(2020\)](#)
219. Montenarh,M. und Götz,C. Protein kinase CK2 and ion channels. [Biomed. Reports 13, 55 \(2020\)](#)



220. Becker,A., Götz,C.,Montenarh,M. und Philipp,S.E. Control of TRPM3 ion channels by protein kinase CK2-mediated phosphorylationin pancreatic beta-cells of the line INS-1. [Int. J. Mol. Sci. 22, 13133, \(2021\)](#)
221. Pack,M., Götz,C., Wrublewski,S. und Montenarh,M. SGC-CK2-1 is an efficient inducer of insulin production and secretion in pancreatic beta-cells. [Pharmaceutics 14, 19 \(2022\)](#).
222. Boewe,A.S., Wemmert,S., Kulas,P., Schick,B., Götz,C., Wrublewsky,S., Montenarh,M., Menger,M.D., Laschke,M.W. und Ampofo,E. Inhibition of CK2 reduces NG2 expression in juvenile angiofibroma. [Biomedicines 10, 966 \(2022\)](#).
223. Pack,M., Gulde,T.N., Völcker,M.V., Böwe,A.S., Wrublewsky,S., Ampofo,E., Montenarh,M. und Götz,C. Proptein kinase CK2 contributes to glucose homeostasis by targeting fructose-1,6-bisphosphatase 1. [Int. J. Mol. Sci. 24, 428 \(2023\)](#)
224. Montenarh,M., Grässer,F.A. and Götz,C. Protein kinase CK2 and Epstein Barr virus. [Biomedicines 11, 358 \(2023\)](#)
225. Montenarh,M. and Götz,C. Protein kinase CK2alpha', more than a backup of CK2alpha. [Cells 12, 2834 \(2023\)](#)
226. Ampofo,E., Pack,M., Wrublewsky,S., Boewe,A.S., Spigelman,A.F., Koch,H., MacDonald,P.E., Laschke M.W. Montenarh,M. und Götz,C. CK2 activity is crucial for proper glucagon expression. [Diabetologia 67, 1368-1385 \(2024\)](#).
227. Götz,C. and Montenarh,M. Protein kinase CK2 contributes to glucose homeostasis. Biol. Chem. in press (2025)